Bioluminescent imaging showed that mice treated with sECM-MSC-ENb-TRAIL had significantly less tumor re-growth as compared to the sECM-MSC-GFP treated group (Fig. 5G) resulting in a significant increase in the median survival of sECM-MSC-ENb-TRAIL treated mice (118 days vs 73.5 days) (Fig. 5H). This evidence concerns the gene TNFSF10 and neoplasm.